A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study

被引：0
|
作者：
Martin H. Stradner
Christian Dejaco
Kerstin Brickmann
Winfried B. Graninger
Hans Peter Brezinschek
机构：
[1] Medical University of Graz,Division of Rheumatology and Immunology
来源：
Arthritis Research & Therapy | / 18卷
关键词：
Rheumatoid arthritis; Biomarker; Rituximab; T cells; Plasmablasts; Lymphocytes;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [1] A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study
    Stradner, Martin H.
    Dejaco, Christian
    Brickmann, Kerstin
    Graninger, Winfried B.
    Brezinschek, Hans Peter
    ARTHRITIS RESEARCH & THERAPY, 2016, 18
  • [2] BARICITINIB IN THE TREATMENT OF PATIENTS WITH MODERATE TO SEVERE ACTIVE RHEUMATOID ARTHRITIS IN CHINA: 24-WEEK RESULTS OF POSTMARKETING SAFETY STUDY
    Wu, C. Y.
    Wang, Q.
    Shi, J.
    Zhang, X.
    Du, R.
    Gu, J.
    Liu, Q. H.
    Yu, J.
    Xu, J. W.
    Zhang, Y. J.
    Zhu, H.
    Li, M.
    Zeng, X.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1418 - 1418
  • [3] Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis
    Walker, Ulrich A.
    Jaeger, Veronika K.
    Chatzidionysiou, Katerina
    Hetland, Merete L.
    Hauge, Ellen-Margrethe
    Pavelka, Karel
    Nordstrom, Dan C.
    Canhao, Helena
    Tomsic, Matija
    van Vollenhoven, Ronald
    Gabay, Cem
    RHEUMATOLOGY, 2016, 55 (02) : 230 - 236
  • [4] Safety and effectiveness of certolizumab pegol in Japanese patients with rheumatoid arthritis: Results from a 24-week post-marketing surveillance study
    Kameda, Hideto
    Nishida, Keiichiro
    Nanki, Toshihiro
    Watanabe, Akira
    Oshima, Yukiya
    Momohara, Shigeki
    MODERN RHEUMATOLOGY, 2023, 33 (03) : 460 - 471
  • [5] Traditional Chinese medicine versus western medicine as used in China in the management of rheumatoid arthritis: a randomized, single-blind, 24-week study
    Yi-ting He
    Ai-hua Ou
    Xiao-bo Yang
    Wei Chen
    Li-yuan Fu
    Ai-ping Lu
    Xiao-ping Yan
    Xing-hua Feng
    Li Su
    Yue-jin Song
    Sheng-ping Zeng
    Wei Liu
    Xian Qian
    Wan-hua Zhu
    Ying-rong Lao
    Wei-hua Xu
    Ze-huai Wen
    Xiao-hong He
    Bao-juan Wang
    Geng-xin Chen
    Su-qin Xue
    Rheumatology International, 2014, 34 : 1647 - 1655
  • [6] Traditional Chinese medicine versus western medicine as used in China in the management of rheumatoid arthritis: a randomized, single-blind, 24-week study
    He, Yi-ting
    Ou, Ai-hua
    Yang, Xiao-bo
    Chen, Wei
    Fu, Li-yuan
    Lu, Ai-ping
    Yan, Xiao-ping
    Feng, Xing-hua
    Su, Li
    Song, Yue-jin
    Zeng, Sheng-ping
    Liu, Wei
    Qian, Xian
    Zhu, Wan-hua
    Lao, Ying-rong
    Xu, Wei-hua
    Wen, Ze-huai
    He, Xiao-hong
    Wang, Bao-juan
    Chen, Geng-xin
    Xue, Su-qin
    RHEUMATOLOGY INTERNATIONAL, 2014, 34 (12) : 1647 - 1655
  • [7] Effectiveness of Rituximab in Patients with Rheumatoid Arthritis: Observational Study from the British Society for Rheumatology Biologics Register
    Soliman, Moetaza M.
    Hyrich, Kimme L.
    Lunt, Mark
    Watson, Kath D.
    Symmons, Deborah P. M.
    Ashcroft, Darren M.
    JOURNAL OF RHEUMATOLOGY, 2012, 39 (02) : 240 - 246
  • [8] Overall infection risk in rheumatoid arthritis during treatment with abatacept, rituximab and tocilizumab; an observational cohort study
    Gron, Kathrine L.
    Glintborg, Bente
    Norgaard, Mette
    Mehnert, Frank
    Ostergaard, Mikkel
    Dreyer, Lene
    Krogh, Niels S.
    Hetland, Merete L.
    RHEUMATOLOGY, 2020, 59 (08) : 1949 - 1956
  • [9] Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study
    Jonathan Kay
    Janusz Jaworski
    Rafal Wojciechowski
    Piotr Wiland
    Anna Dudek
    Marek Krogulec
    Slawomir Jeka
    Agnieszka Zielinska
    Jakub Trefler
    Katarzyna Bartnicka-Maslowska
    Magdalena Krajewska-Wlodarczyk
    Piotr A. Klimiuk
    Sang Joon Lee
    Yun Ju Bae
    Go Eun Yang
    Jae Kyoung Yoo
    Daniel E. Furst
    Edward Keystone
    Arthritis Research & Therapy, 23
  • [10] Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study
    Kay, Jonathan
    Jaworski, Janusz
    Wojciechowski, Rafal
    Wiland, Piotr
    Dudek, Anna
    Krogulec, Marek
    Jeka, Slawomir
    Zielinska, Agnieszka
    Trefler, Jakub
    Bartnicka-Maslowska, Katarzyna
    Krajewska-Wlodarczyk, Magdalena
    Klimiuk, Piotr A.
    Lee, Sang Joon
    Bae, Yun Ju
    Yang, Go Eun
    Yoo, Jae Kyoung
    Furst, Daniel E.
    Keystone, Edward
    ARTHRITIS RESEARCH & THERAPY, 2021, 23 (01)
12345